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1. Introduction 
1.1 Evolving profile of heart failure  
There have been many definitions of Heart Failure and yet the most recent definitions rely 
heavily on clinical manifestations: dyspnoea or undue fatigue on exertion, along with the 
evidence of fluid retention, supported by objective evidence of structural or functional 
abnormalities of the heart at rest. A more recent classification also recognizes and 
emphasizes the need for the above signs and symptoms for both the development and 
progression of heart failure (Dickstein et al., 2008). The 2009 update of the AHA guideline 
identifies patients at higher risk of developing or progressing more rapidly to heart failure 
as traditionally defined. Table 1. 
The presence of cardio-metabolic risk factors (hypertension, diabetes, obesity and metabolic 
syndrome) in addition to atherosclerotic disease puts the patient at twice greater risk of 
developing and/or progressing to heart failure as currently defined i.e. with structural or 
functional heart disease at rest. Studies across the world, particularly in India, China and 
Latin America suggest that overweight, metabolically challenged individuals are at greater 
risk of heart failure at a younger age and are also twice as likely to have heart failure linked 
events such as hospitalization or mortality (Clarke et al., 2010).  
Echocardiography and Doppler imaging of the heart are the current gold standards for 
identification of structural and to extent also functional abnormalities. Advances in 
Echocardiography and Doppler imaging have enabled the identification of an under-
diagnosed entity described as diastolic dysfunction, an additional handicap for a failing 
heart. Prognosis of patients with predominant diastolic dysfunction (Heart Failure with 
Preserved Ejection Fraction: HFPEF) has been reported to be similar to those who have 
predominant systolic dysfunction. In some population surveys, up to 50% of patients fall in 
this category (Paulus, 1998). Many have co-morbidities identified as risk factors in Stage A 
of the AHA classification. It is therefore pertinent to understand why and how these 
additional risk factors influence the development and progression of heart failure as 
different from and often in addition to Atherosclerotic Coronary Artery Disease. 
Diabetes, hypertension, dyslipidemia and thyroid dysfunction affecting heart are often 
considered as factors contributing to coronary artery disease. However, there is evidence to 
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suggest that diabetes and hypertension may affect myocardial function largely independent 
of significant epicardial coronary artery disease. The main objective of this chapter is to 
explain holistic effects of cardio-metabolic risk factors on heart failure. We urge the reader to 
consider factors beyond the myocardium, such as vascular responsiveness, neuroendocrine 
maladaptation and renal function and correlate it with clinical manifestations. This chapter 
elucidates and correlates recent advances in understanding of etiological factors affecting 
the myocardial function, the mechanisms which could be influencing overall progression 
and presentation of heart failure, current diagnostic approaches, their limitations and 
emerging concepts, current medical therapies, their limitations and newer emerging 
therapeutic approaches. 
 
 
 
Subjects at Risk for Heart Failure
STAGE A
High risk for HF
Non symptomatic
No structural defects
PATIENTS WITH
– Hypertension
– Atherosclerotic disease
– Diabetes
– Obesity
– Metabolic syndrome
or
– Using cardiotoxins
– With FHx CM
THERAPY
Goals
• Treat hypertension
• Encourage smoking cessation
• Treat lipid disorder
• Encourage regular exercise
• Discourage alcohol intake
• Control metabolic syndrome
Drugs
• ACEI or ARB in appropriate 
patients for vascular disease or 
diabetes 
STAGE B
Non symptomatic
Structural defects present
PATIENTS WITH
– Previous MI
– LV remodeling including LVH & low EF
– Asymptomatic valvular disease
THERAPY
Goals
• All measures under stage A
Drugs
• ACEI or ARB 
•  blockers
Devices
• In selected patients: Implantable 
defibrillators
 
 
 
 
Table 1. Stages in the development of heart failure and recommended therapy by stage. 
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; EF, 
ejection fraction; FHx CM, family history of cardiomyopathy; HF, heart failure; LVH, left 
ventricular hypertrophy; and MI, myocardial infarction. Modified from Jessup M, Abraham 
WT, Casey DE et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and 
management of heart failure in adults (Jessup et al., 2009). 
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2. Cardio-Metabolic Cardiomyopathy (CMCM) 
The etiology of cardiomyopathy associated with diabetes is widely debated. While 
hyperglycemia is regarded as a sole culprit in causation of diabetic cardiomyopathy, there 
is a cluster of associated risk factors - obesity, hyperlipidemia, prothrombotic state, 
hypertension, activation of multiple hormone and cytokine systems etc, which are 
commonly seen in most patients presenting with diabetes of more than five years and 
these in turn have intricate effects in causation of cardiomyopathy. More and more 
researchers are now focusing on the overall impact of diabetes and cluster of these 
observable conditions on altered metabolism and energetics at cellular level of the target 
end organs, which are known to be most vulnerable to such altered conditions. Increasing 
evidence are now available which suggest that altered myocyte functioning is more a 
function of altered cellular metabolism. It is seen that simultaneous over-activation of 
renin-angiotensin-aldosterone system (RAAS), increased oxidative stress and 
compromised endothelial function, contributed by each individual component adds to 
overall dysfunction of myocardium. Effect on peripheral vasculature adds on to the 
already stressed myocardium and predispose to an early compromise in over all 
cardiovascular functions. 
Many of the changes described occur in predisposed individuals even before the onset of 
diabetes, often at the stage when they may be diagnosed as having pre-hypertension or 
impaired glucose tolerance. There is therefore a need for holistic terminology which could 
represent contribution of not only of diabetes and associated hyperglycemia but equally 
of other factors – obesity, dyslipidemia, hypertension, in the pathogenesis of 
cardiomyopathy, for which the term “Cardio-metabolic Cardiomyopathy (CMCM)” seems 
appropriate (Fig. 1). The terminology CMCM is based on available evidence of altered  
 
 
Fig. 1. Various possible risk factors that could contribute to the development of Cardio-
metabolic  Cardiomyopathy (CMCM). 
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myocytes metabolism and energetics leading to cardiomyopathy. This would need further 
support from ongoing and future research to consolidate itself as a new class of 
cardiomyopathy representing cluster of metabolic derangement and altered energetics of 
myocytes with a common underlying derangement – diminishing flexibility to use the 
appropriate fuel to provide adequate energy, resulting in dysfunctional mitochondria. 
2.1 Mechanisms of CMCM 
2.1.1 Myocardial metabolism in normal heart 
A normal healthy heart uses free fatty acid (FFA) as its preferred fuel source and to a lesser 
extent, circulating glucose (Fig 2). In case of severe starvation it can also utilize lactate,  
 
 
 
Fig. 2. Myocardial metabolism in normal heart. Normal myocardium at resting state uses 
FFA as a preferred fuel source, which is energy rich substrate but yield less ATP per mol of 
O2. While in the state of increased peripheral physiological demand (e.g. exercise) 
myocardium uses glucose as energy source which is more efficient energy source and yield 
more ATP per mol of O2.. ATP, Adenosine triphosphate; FFA, Free fatty acid; O2, oxygen; 
Pcr, Phospho creatinine. 
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ketone bodies and amino acids. The regulation of myocardial metabolism is dependent on 
the availability and abundance of substrate, hormone levels, coronary blood flow and 
oxygenation and inotropic state of the tissue. With ageing, relative contribution of glucose as 
myocardial substrate increases as seen in elderly.  The levels of FFA determine its uptake by 
myocytes. Following uptake and conjugation with acetyl CoA (FA-CoA), FA-CoA enters the 
mitochondria, via the carnitine acyl transferase shuttle (CPT-1 and CPT-2). CPT-1 is subject 
to allosteric regulation by malonyl CoA and effective transfer to the mitochondria requires 
adequate amounts of carnitine (Abel & Doenst, 2011). Upon entering the mitochondrial 
matrix, FA-CoA undergoes -oxidation. Post prandial, higher levels of insulin in blood 
increases muscle glucose uptake by increasing glucose transporters (GLUT-1 and GLUT-4) 
translocation and by suppressing FFA release from adipose tissues thereby removing FFA 
mediated inhibition of glycolysis and pyruvate oxidation. 
2.1.2 Metabolic disturbances in cardio-metabolic cardiomyopathy (CMCM) 
There are many factors considered as initiators to the functional and structural alterations 
which contribute to the development and progression of CMCM. Most of these evidence are 
from animal experimental studies. Though development of CMCM is multi-factorial, 
metabolic disturbance is the major culprit. 
2.1.2.1 Altered fuel supply and altered substrate utilization 
Increasing evidence suggests that altered substrate supply and utilization by cardiac 
myocytes could be the initial trigger in the pathogenesis of CMCM. Under deranged 
metabolic milieu, inclusive of diabetes, heart use relatively more fat than normal heart 
(Herrero et al., 2006; Carley & Severson, 2005). The shift towards increased fatty acids and 
decreased glucose utilization is linked to elevated circulating levels of FFA and triglycerides 
as a consequence of enhanced adipose tissue lipolysis, increased FFA uptake as well as high 
tissue FFAs caused by hydrolysis of augmented myocardial triglyceride stores. Animal 
studies in db/db mice, (a model of type II diabetes with obesity and hyperglycemia), have 
shown increased cell membrane fatty acid (FA) transporters (FAT/CD36) and FA binding 
proteins leading to increased FA uptake in db/db mice hearts (Carley & Severson, 2008). To 
handle this increased FA, there is upregulation of mitochondrial enzymes involved in fat 
metabolism. 
The reduced glucose utilization seen in such condition is partly accounted for by the slow 
rate of glucose transport across the sarco-lemmal membrane into the myocardium, which is 
probably due to the cellular depletion/reduced translocation of GLUT-4 caused by insulin 
resistance (Garvey et al., 1993). High circulating FFA and increased FA oxidation inhibits 
pyruvate dehydrogenase complex thereby reducing glucose oxidation.  
Exercise influences myocardial glucose utilization, perhaps independent of insulin levels. 
Graded exercise in all cases of heart failure has been documented to be beneficial. It is likely 
that exercise has a beneficial effect in maintaining the substrate flexibility of the 
myocardium. 
2.1.2.2 Lipotoxicity associated with excessive accumulation of intracellular lipids 
When FA uptake exceeds FA oxidation capabilities, lipid accumulation occurs resulting in 
lipotoxicity. This is evident in diabetics and obese patients but not seen in non-obese. High 
circulating and cellular FFA necessitates abnormal higher oxygen demand during FFA 
metabolism in addition to enhancing peripheral insulin resistance. This results in accumulation 
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of toxic intermediates of FFA metabolism leading to impaired functional performance. Fuel 
surplus is likely to activate peroxisome proliferators-activated receptor (PPAR-┙) with 
subsequent increase in FA oxidation. Accumulation of palmitate results in increased free radical 
production and endoplasmic reticular stress which leads to apoptosis (Borradaile et al., 2006). 
Palmitate accumulation can also promote denovo ceramide production which is also an inducer 
of apoptosis. Carnitine, an essential substrate for myocardial FFA metabolism is reduced along 
with abnormal appearing mitochondria (Ashrafian et al., 2007). 
Thus, impaired substrate flexibility and inefficient adenosine triphosphate (ATP) generation, 
resulting in inability in fulfillment of myocardial energy demand, initially on exertion, 
progressing to inadequacy at rest, is the hallmark of CMCM.  
2.1.2.3 Increased generation of advanced glycation and lipoxidation end products along 
with reactive oxygen species affecting heart in altered metabolic conditions 
Advanced glycation end products (AGEs) and advanced lipoxidation end products 
(ALEs) are formed when carbohydrate- or lipid-derived intermediates react with the 
amino group of proteins to form covalently modified, stable protein adducts. AGEs/ALEs 
formation results from a combination of hyperglycemia, hyperlipidemia, 
oxidative/carbonyl stress and/or decreased renal clearance (Miyata et al., 2001). These 
modifications may be a single change on the peptide chain or multiple modifications that 
can produce crosslinks within or between proteins. Long-lived proteins like collagen and 
elastin are highly vulnerable for crosslink formation with AGEs and ALEs. These 
modifications lead to impaired collagen degradation and thereby increased collagen 
accumulation and subsequent fibrosis.  
AGEs accumulation exert their detrimental effect on cardiac structure and function by 
different mechanisms. Firstly, structural modification/crosslinkage of myocardial proteins 
involved in cardiac contraction or relaxation may occur, resulting in impaired systolic or 
diastolic function and structural alteration. By disrupting intra- and inter-domain tertiary 
structures of Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA2a), AGE complexes 
have shown to compromise structural movements required for translocating calcium ions 
from the cytosol to the lumen of the sarcoplasmic reticulum. Secondly, AGEs promote trans-
differentiation of epithelial cells to myofibroblasts via their specific receptors (e.g., RAGE). 
Finally, activation of RAGE promotes inflammation and oxidative stress, which can decrease 
the bioavailability of nitric oxide. This may result in further increased oxidative stress and 
attenuated contribution of nitric oxide during myocardial relaxation (Goldin et al., 2006). Thus, 
AGE-RAGE interaction can have a direct functional impact on myocardial relaxation. There is 
also increased free radical generation and oxidative stress with subsequent activation of many 
deleterious pathways which lead to apoptosis and cell death. Effects of AGEs leading to 
increased stiffness of connective tissue, increased permeability and pro-coagulant state due to 
effects on endothelial functions, increased vascular matrix through mononuclear cell activation 
and defective vascular relaxation due to decreased nitrous oxide (NO) release, run hand in 
hand, with direct effects on heart and contribute to overall patho-physiology of CMCM. 
Although many studies have not been reported with ALEs, yet, recent evidence suggests 
that ALEs induce inflammatory pathways and network similar to AGEs leading to vascular 
complications (Shanmugam et al., 2008). ALEs and AGEs go hand in hand from their 
generation to effect on different end organs and are not limited to diabetes. Effects of ALEs 
on myocardium in isolation, could be similar to AGEs, however, need further studies for 
better understanding. 
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2.1.3 Dysfunctional calcium homeostasis 
Calcium, essential for the process of excitation–contraction, is the primary ionic regulator 
in the heart. In Type 2 rodent models of diabetes, altered expression, activity and 
function of many regulatory and contractile proteins/transporters involved in 
excitation–contraction coupling; SERCA, Na+/Ca2+ exchange (NCX), ryanodine receptors 
(RyR) and plasma membrane Ca2+-ATPase (PMCA), as well as dysfunctional 
intracellular calcium signaling, have been reported (Pereira et al., 2006; Vetter et al., 
2002). These alterations have been attributed to accumulation of toxic molecules such as 
long-chain acylcarnitines, free radicals and abnormal membrane lipid content as well as 
to AGEs altering the structure and function of several proteins described above. The 
consequences of these changes include alterations to the calcium sensitivity of regulatory 
proteins involved in the regulation of the cardiac actomyosin system, possibly due to 
phosphorylation of sarcomeric protein troponin I. The diminished calcium sensitivity 
and altered activity of regulatory and contractile proteins may all contribute to impaired 
left ventricular (LV) function. 
2.1.4 Altered thyroid hormone status 
Recent evidence indicates that heart failure can lead to down-regulation of the thyroid 
hormone signaling system in the heart. In the failing heart, there is decrease in thyroid 
hormone receptor expression; in addition, serum levels of T4 and T3 are decreased with 
heart failure in the frame of the non-thyroidal illness syndrome (Kinugawa et al., 2001). 
Thyroid hormone levels have a profound impact on mitochondria, the organelles 
responsible for the majority of cellular ATP production. The hypermetabolic effects of 
thyroid hormones are partially due to an increased demand for ATP and partially due to 
increased uncoupling. In addition, thyroid hormones are potent activators of 
mitochondriogenesis. Key events in thyroid-hormone-induced mitochondriogenesis include 
the increased expression of the mitochondrial transcription factors, nuclear respiratory 
factor-1 (NRF-1) and peroxisome-proliferator-activated receptor gamma co-activator-1a 
(PGC-1a). In addition, transcriptional and post-transcriptional mechanisms are important 
for the effects of T3, for example, in the synthesis of cytochrome c oxidase subunits. Thus, 
thyroid hormones are key regulator of mitochondrial energetics. In animal models, it has 
been shown that in pressure overload-induced cardiac hypertrophy a decrease of thyroid 
hormone receptor level occurs. The decrease in T3 serves as an indicator for a bad prognosis 
in the heart failure patient being linked to increased mortality (Dillmann, 2010). 
2.1.5 Up regulated renin-angiotensin-aldosterone and sympathetic system 
RAAS and sympathetic system are profoundly dysregulated in metabolic deranged 
conditions and adipose tissue has a full local renin-angiotensin system that is active at local 
and systemic level (Sarzani et al., 2008). RAAS is considered to have a prime role in 
hypertensive cardiomyopathy even though several growth factors influence initiation and 
maintenance of myocardial hypertrophy. Both angiotensin II and aldosterone are shown to 
contribute to myocardial fibrosis (Sopel et al., 2011; Struthers & Unger, 2011). Correlation 
between circulating renin–angiotensin levels and left ventricular mass have long been 
established and same has been proved by the study showing regression of hypertensive left 
ventricular hypertrophy upon targeting RAAS (Solomon et al., 2009). Though synergistic 
effects of angiotensin II and aldosterone are well established with regard to perivascular and 
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interstitial fibrosis of the ventricle; angiotensin-independent effect of aldosterone on 
myocardial fibrosis has also been demonstrated. Current evidence shows that aldosterone 
has some role in the transition of left ventricular hypertrophy to cardiac failure. In addition, 
aldosterone also has a role in fluid retention. Altered RAAS has implication in chronic 
kidney disease and impaired kidney function resulting in volume overload which results in 
exacerbation of symptoms of heart failure and disease progression. 
In addition to high RAAS drive, sympathetic hyperactivity present in patients with 
deranged metabolic profile contributes not only to high blood pressure, but seems to have 
further adverse metabolic effects also, such as insulin resistance, hyperinsulinaemia and 
hyperlipidaemia. Experimental evidence has indicated that heightened sympathetic nervous 
system activity facilitates the development of myocardial hypertrophy in animals and 
humans. Antihypertensive vasodilators (hydralazine and minoxidil) which are known to 
have some stimulating effect on sympathetic nervous system fail to reduce left ventricular 
hypertrophy despite their well-documented antihypertensive effects (Elliott et al., 2008). 
Thus, if such a relationship between RAAS, sympathetic activation and left ventricular 
hypertrophy exists, there are all possibilities that cardiomyopathy in hypertensive patients 
may be resultant of this interaction. This becomes more evident especially since 
neuroendocrine activation is found in hypertensive cardiomyopathy, with activation of the 
RAAS and the sympathetic system. All these components are hypothesized to be constituent 
part of CMCM as both RAAS and sympathetic systems are up-regulated in them.  
2.1.6 Diastolic dysfunction, systolic dysfunction and ventricular hypertrophy in 
CMCM 
Ventricular diastolic function is dependent on an active relaxation process in conjunction 
with passive elastic properties of the myocardium. In diastolic dysfunction, there is 
impairment in ventricular relaxation and passive filling. About 75% of diabetics show this 
dysfunction which is more pronounced when other metabolic abnormalities co-exist. In 
diastolic heart failure, though the ejection fraction may be normal, there is diastolic 
dysfunction along with elevated end diastolic pressure.   
Functional abnormalities occur as a result of structural remodeling. In diastolic dysfunction 
a moderate increase in left ventricular mass and an elevated ventricular wall thickness to 
chamber radius is seen (Ozasa et al., 2008). The end diastolic volume is nearly normal. 
Increase in AGE crosslinks of cardiac SERCA impairs the ability or capacity of SERCA to 
translocate calcium and thus slows the rate of cardiac relaxation. The reduction in elasticity 
of the myocardium is due to myocardial collagen deposition and AGE crosslinks with 
elastin (Van et al., 2008). This early cardiac dysfunction, along with other exacerbating risk 
factors accelerates the decline in cardiac function.  
Under conditions of hyperinsulinemia, a basic component of increased cardio-metabolic 
risks, insulin stimulates hypertrophy in cardiomyocytes by several pathways, mainly by 
activation of Akt and ERK. Increased circulating angiotensin II induces cardiomyocyte 
hypertrophy and interstitial fibrosis (He et al., 2005). Angiotensin II is also reported to 
increase reactive oxygen species (ROS) production and excess ROS produces cardiomyocyte 
death and results in replacement fibrosis. Sympathetic activation, in addition to effects on 
blood pressure, seems to have adverse metabolic effects. Hence, the interstitial fibrosis, 
protein glycosylation and myocyte hypertrophy are likely factors contributing to reduced 
diastolic compliance and ventricular hypertrophy in CMCM patients. 
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In the presence of predominant diastolic dysfunction, supervening reduced systolic reserve 
is often overlooked by diagnostic imaging at rest. Increased intracellular fatty acids and its 
metabolites are toxic to the mitochondria and induce apoptosis and damage the contractile 
apparatus. Many studies have demonstrated that the inhibitory cardiac troponin-I (cTnI) 
expression is markedly raised in the heart of diabetic rats and in cardiac hypertrophy. 
GATA binding protein 4 (GATA-4) binding site in the proximal region of cTnI gene is 
necessary for the transcriptional activation of this gene. GATA-4 found in cardiac myocytes 
regulates many other cardiac-specific gene expressions, like angiotensin II (AT1A) and 
endothelin-1 (ETA) receptors, atrial natriuretic factor (ANF), beta-type natriuretic peptide 
(BNP), myosin heavy chain (MHC) etc. Studies have shown that activation of MEK/ERK 
pathway by hyperglycemia-induced ROS or by direct adrenergic stimulation, increase 
GATA-4 phosphorylation and nuclear translocation, in addition MEK/ERK activation also 
causes GSK3┚ phosphorylation, thereby lowering the export of GATA-4 from nucleus, 
leading to GATA-4 preservation in the nucleus, which finally leads to an increase in the 
expression level of cTnI resulting in reduced cardiac contractility (Ku et al., 2011). 
The longitudinal fibres responsible for long-axis contraction lie in the sub-endocardium and 
are particularly susceptible to the effects of fibrosis, ischemia or hypertrophy. Initially the 
long-axis systolic dysfunction is associated with a compensatory increase in radial 
thickening and mass, thus preserving left ventricular ejection fraction (LVEF). The 
preservation of ejection fraction is directly related to the presence of LV hypertrophy and 
the effect of increased muscle mass. However, reserve systolic functions are reduced and 
these patients show enhanced systolic functional abnormalities only during stress or 
exercise. Clinical studies have demonstrated that diabetic patients have an increased end-
systolic diameter and volume, a diminished ejection fraction and a decreased minor axis 
shortening and velocity of circumferential fiber shortening in the absence of coronary artery 
disease. This is exaggerated when exposed to stress like exercise. These dysfunctions 
coupled with dysfunction in peripheral vasculature in CMCM translate into profound 
compromise in overall exercise reserve. 
2.2 A central role for mitochondrial dysfunction in CMCM 
2.2.1 Normal role of mitochondria 
Myocardial contractile function is energy (ATP) dependent. Mitochondria are the major site 
of substrate oxidation and ATP production in cardiomyocytes. In addition, mitochondria 
also contribute to intracellular ROS generation. It is by oxidative phosphorylation in the 
mitochondrial system through which the oxidation of energy substrates in a cell is coupled 
to the activity of ATP synthase in the mitochondrial inner membrane. The activity of ATP 
synthase is powered by the electrochemical gradient existing across the mitochondrial inner 
membrane. The ATP produced drives energy demanding reactions not only in the 
mitochondrion but also in the cytoplasm.  
2.2.2 Abnormal mitochondrial morphology and function 
Lines of evidence have shown that mitochondrial dysfunction contributes to the 
development of insulin resistance and metabolic syndrome. The causes of mitochondrial 
dysfunction are complex, but over-nutrition and sedentary life style are among the best 
known causes of mitochondrial dysfunction (Kim et al., 2008). The cardio-metabolic 
conditions such as insulin resistance, diabetes, hypertension, dyslipidemia and sub-clinical 
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hypothyroidism are characterized by altered mitochondrial function. Visceral obesity and 
related cardio-metabolic disorders are linked to defective mitochondrial biogenesis and 
oxidative metabolism with decreased ATP production. The hypertrophy-related changes in 
myocardium are likely related to mitochondrial structural and functional alterations that 
leads to altered mitochondrial efficiency for substrate oxidation and ATP production. 
Studies have revealed distinct patterns in mitochondrial structural and functional alterations 
in pathological and physiological cardiac hypertrophy. Among many signaling pathways 
that conspire to impair mitochondrial function include, decreased expression or activity of 
transcriptional regulators that govern mitochondrial biogenesis and oxidative capacity (i.e. 
PGC-1, ERR, and PPAR-) and decreased transcription of mitochondrial DNA. Increased 
G-protein-coupled receptor signaling activates Class1B PI3K that leads to constitutive 
activation of Akt, which may repress mitochondrial function. Activation of HIF-1 leads to a 
PPAR- mediated increase in FA uptake and lipogenesis that may promote lipotoxicity, 
which could further impair mitochondrial function. Reduced cardiolipin content and 
remodeling of the mitochondrial proteome also contribute to mitochondrial dysfunction. 
Mitochondrial dysfunction promotes oxidative stress that leads to a vicious cycle of 
progressive mitochondrial damage.  
At functional level, activities of mitochondrial complex I and III reduce at the stage of 
compensated cardiac hypertrophy, but this is accompanied by reduced mitochondrial ROS 
and oxidative damage that only becomes evident after the transition to heart failure. 
Hypertrophied hearts do not lose mitochondrial membrane potential in the context of 
ischemia and re-perfusion injury. However, the increase in mitochondrial membrane 
potential correlates with an increased risk of arrhythmias. By the time compensated 
hypertrophy progresses to pathological LV hypertrophy, altered mitochondrial morphology 
and function are evident. Pathological hypertrophic cardiomyopathy displays swollen 
cardiac mitochondria with disrupted cristae and substantial mitochondrial DNA depletion.  
Mitochondrial membrane permeabilization is a rate limiting step of apoptosis and is 
mediated by the mitochondrial permeability transition pore (mtPTP). mtPTP is a nonspecific 
pore, permeable to all molecules of less than 1.5 kDa and is formed by the voltage-
dependent anion channel (VDAC), members of the pro- and anti-apoptotic Bax/Bcl2 protein 
family, cyclophilin D and adenine nucleotide translocase (ANT). The ANT mediates 
nucleotide transfer from mitochondria to cytosol. The ATP synthesized in the mitochondria 
is exchanged for cytosolic adenosine diphosphate (ADP) by ANT to provide a continuous 
supply of ADP to mitochondria. ATP/ADP exchange by ANT is essential for the 
maintenance of ATP synthase activity.  
On the other hand, in states of impaired function of ATP/ADP exchange, ANT plays a 
major role in generating ROS and inducing cell apoptosis (Kim et al., 2010). Thus, impaired 
ANT activity could contribute to deficient energy availability in pathological cardiac 
hypertrophy. Reduced level of cardiac ANT has been reported in some, but not all models of 
pressure overload cardiac hypertrophy. Additional proteins that were proposed to be part 
of the mtPTP complex are hexokinase, creatine kinase, and peripheral benzodiazepine 
receptor. mtPTP opening causes swelling of the mitochondrial matrix and rupture of outer 
membrane. 
Cardiolipin, an important component and one of the most abundant phospholipid of the 
inner mitochondrial membrane, is essential for the optimal function of numerous enzymes 
that are involved in mitochondrial energy metabolism, where it regulates the activity of the 
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mitochondrial electron transport chain, ATP synthesis and mitochondrial bioenergetics 
(Abel & Doenst, 2011). Abundance of linoleic acid and close proximity to the site of ROS 
production, i.e. the inner mitochondrial membrane make cardiolipin particularly more 
susceptible to damage by oxidative stress. Cardiolipin is identified as the only phospholipid 
in mitochondria that undergoes early oxidation during apoptosis (Kagan et al., 2005). 
Cardiolipin peroxidation by ROS thus affects its binding with cytochrome c and affects the 
activity of complex I, III, and IV of the mitochondrial respiratory chain (Paradies et al., 
2004). Mitochondrial cardiolipin content is reduced in heart failure and 
ischemia/reperfusion and correlates with reduced electron transport chain activities. 
Patients with obesity and insulin resistance have poorer outcomes after myocardial 
infarction compared with lean subjects. These changes are associated with reduced 
myocardial cardiolipin content (Sparagna et al., 2007). Thus, reduced myocardial cardiolipin 
content contributes to the reduced mitochondrial efficiency in diabetes and metabolic 
syndrome and may exacerbate the progression of CMCM. 
3. Diagnosis 
Cardiac dysfunction caused by a constellation of metabolic abnormality may have variety of 
presentations. On one hand it includes myocardial dysfunction and coronary artery disease 
and on the other hand it may be arrhythmias and sudden death. When a patient presents 
with features of heart failure like, exercise intolerance, fatigue, and dyspnea with exertion as 
prominent symptoms in background of metabolic abnormalities like impaired glucose 
metabolism, dyslipidemia and hypertension with or without subclinical hypothyroidism 
then CMCM should be considered. 
Clinical assessment of patients of heart failure with metabolic disorder  should start with a 
thorough history followed by evaluation of pulmonary function to rule out non cardiac 
causes of dyspnoea. This should be followed by evaluation of functional limitations and 
status of the structural defect in the heart. Thereafter, causes of heart failure and extent of 
compromise in hemodynamic (perfusion and volume) status should be assessed. Because 
progression of heart failure is relatively rapid in metabolically challenged patients, it is very 
important to identify defects early in asymptomatic patients in order to prevent progression 
to symptomatic disease. 
Laboratory evaluation of patients should start with complete blood count, urinalysis, 
serum electrolytes, blood urea nitrogen, serum creatinine, fasting blood glucose 
(glycohemoglobin), lipid profile and liver function tests. Thyroid dysfunctions may be 
subclinical with normal serum free T4 (fT4), free T3 (fT3) levels but deranged  serum 
thyroid stimulating hormone (TSH) levels. Use of biomarkers for diagnosis of heart 
failure includes a number of neuroendocrine hormones, including norepinephrine, 
angiotensin II, renin, aldosterone, vasopressin and most recently BNP. Association of 
abnormal levels of these biomarkers with abnormal myocardial function and the 
unfavorable prognostic significance are increasingly being recognized and used. Patients 
with history of diabetes and elderly patients who are at high risk of developing 
myocardial dysfunction have a high prevalence of elevated plasma BNP levels. Thus, 
these high risk populations with elevated plasma levels of BNP or NT-proBNP can be 
identified for detailed evaluation of cardiac functions by echocardiography and/or 
cardiopulmonary exercise testing (CPET).  
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Insulin resistance can be an important etiologic factor in the development of heart failure 
with metabolic disorder as adaptive responses of myocardium to different stress are 
compromised in presence of insulin resistance. Insulin resistance has strong correlation with 
development of hypertension, left ventricular hypertrophy and left ventricular dysfunction 
and subsequent development of heart failure. There is also increased prevalence of 
myocardial ischemia in patients with insulin resistance and heart failure itself causes insulin 
resistance (Wilson, 2001; Nikolaidis et al., 2004). Evidence of insulin resistance should be 
evaluated by measuring fasting insulin levels.  
Assessment of myocardial wall thickness, LV size and pericardium by comprehensive two-
dimensional Echocardiography along with Doppler imaging are useful diagnostic tests in 
the evaluation of patients of heart failure. The most common abnormality associated with 
insulin resistance and diabetes mellitus is abnormality in diastolic function which is 
independent of ischemic heart disease (Fang et al., 2004; Schannwell et al., 2002). Evaluation 
of ventricular filling pattern by color Doppler imaging evaluating diastolic dysfunction 
becomes important for diagnosing such symptomatic patients who have preserved ejection 
fraction. A comprehensive echocardiographic examination helps in these distinctions when 
more than one abnormality affects the cardiac functions. 
Most of the above mentioned methods of evaluation examine patients at rest, thus have 
limitations. Physical limitations during exercise, like shortness of breath and fatigue are 
caused by dynamic dysfunctions in myocardium occurring under stress and may not 
manifest at rest. Thus, markers of diminished cardiac reserve often go undetected by 
echocardiography. Stress echocardiography can detect ventricular dysfunction including 
wall motion abnormalities (hypokinesia, akinesia, dyskinesia or diastolic dysfunction) when 
exposed to stress either by dobutamin or exercise. This can pick up early cases with 
compromsied ventricular functions, however, peripheral components of heart failure may 
still not be factored in it.  
CPET is a well-established method of evaluating cardiopulmonary functions in heart failure. 
This is highly reproducible measurement and helps in differentiation of cause of symptoms 
associated with heart failure. Using CPET for evaluation of limitation in cardiac functions in 
the patients with heart failure associated with metabolic disorder will not only evaluate 
dynamic response of heart to physiological stress but also peripheral component of 
hemodynamics which often coexists. Symptoms such as fatigue and disproportionate 
dyspnoea may be explained by inadequate and inappropriate vascular responsiveness 
(capillary recruitment) to demand generated by exercising skeletal muscles (Joshi et al., 2010). 
Maximal aerobic capacity (peak VO2), Ve/VCO2 and oxygen uptake efficiency slope (OUES) 
parameters obtained from CPET aids in early diagnosis of subtle pathology and helps in 
following the progression of the disease. These have important prognostic value also. 
Impedance cardiography can be used non-invasively to measure hemodynamic parameters 
to diagnose covert cases of CMCM. Experimental studies in diabetic patients measuring 
stroke volume and cardiac output by impedance cardiography at the time of rest and 
exercise suggest, compromise in cardiac reserve even in the absence of any clinical 
symptoms of heart failure (Joshi et al., 2010). Compromise in cardiac reserve was 
contributed to, by an inappropriate increase in stroke volume due to diastolic compromise 
exaggerated by increase in heart rate. There was decrease in stroke volume and it had to be 
compensated for, by further increase in heart rate to maintain cardiac output. This “inflexion 
point”, the heart rate at which the stroke volume starts decreasing, occurred at a relatively 
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low heart rate. Recent evidence that limiting heart rate increase has favorable outcome in 
heart failure independent of beta blockade suggests ways of managing this dysfunction 
(Swedberg et al., 2010). There is speculation as to what should be the target heart rate to be 
achieved with such therapy. Perhaps studies such as done by Joshi et al., may provide the 
answer. 
4. Treatment 
Routine management of heart failure depending upon the status of decompensation, should 
be integral part of any case of CMCM. Along with this, therapy directed to pathophysiology 
like insulin resistance, hypothyroid state, lipid abnormality and therapies modulating the 
metabolic properties of myocytes should be considered.  
4.1 Improving insulin resistance 
Therapies which reduce insulin resistance improves outcome. There are evidence to support 
that therapies directed to treat heart failure also reduce insulin resistance even in non-heart 
failure population. Similarly, exercise improves both heart failure outcome and insulin 
sensitivity in non-ischemic heart failure (Kemppainen et al., 2003). Angiotensin converting 
enzyme inhibitor and angiotensin receptor blockers also improve insulin sensitivity in 
addition to their effect on heart failure (Yusuf et al., 2000; Pfeffer et al., 2003). 
Drug therapy improving insulin resistance in CMCM can be at multiple levels. Different 
approaches consisting of lowering circulating FFA levels, facilitating glucose uptake and 
metabolism have been identified. These can be both anti-diabetic medication and metabolic 
modulator. 
Drugs improving insulin sensitivity like metformin and thiazolidinediones are expected to 
improve outcome in cardiomyopathy associated with insulin resistance. Metformin can also 
improve calcium handling in myocytes (Ren et al., 1999), however, potential of causing lactic 
acidosis limits its utility in heart failure, especially in the context of renal dysfunction. 
Insulin or insulin-secretagogues could be another option as they directly promote glucose 
metabolism and decrease circulating FFAs but they have also failed in different animal 
models (Ren et al., 1996). Insulin therapy is expected to reduce catecholamine-induced 
myocardial damage in the heart however like with thizolidinediones, there is danger of fluid 
retention and hypoglycemia that may be detrimental. Several studies attempting to 
demonstrate the beneficial effects of tight glycemic control with insulin and secretagogues 
have failed to show any superiority and in fact have resulted in higher cardiovascular 
events. 
Under the circumstances of insulin resistance, the body's compensatory mechanisms 
(hyperinsulinemia, up-regulation of the RAAS, catecholamines, vasopressin) are 
maladaptive and can further worsen the cardiomyopathy. Many counter-regulatory 
hormones like epinephrine, norepinephrine, glucagon, cortisol, growth hormone are 
upregulated and increases insulin resistance and alter glucose disposition (Nikolaidis et al., 
2004). They also contribute to the pathogenesis of cardiomyopathy. Adrenergic blockade 
with carvedilol, long acting metoprolol and nebivolol improves myocardial efficiency by 
reducing consumption of FFA by myocardium and increasing preference to glucose as fuel 
(Nikolaidis et al., 2006) because chronic stimulation of beta-receptor seen in cardiac 
decompensation is known to inhibit insulin-mediated glucose uptake and insulin receptor 
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activation (Morisco et al., 2005). These patients are expected to achieve dramatic responses 
to angiotensin converting enzyme inhibition and beta-adrenergic blocking therapy, often 
with recovery of LVEF to normal or near-normal levels. 
Limiting increase in heart rate independent of beta blockade has been shown to be of benefit 
in heart failure; ivabradine therapy in patients with systolic dysfunction and resting sinus 
rhythm of more than 70 bpm despite beta blockers or in beta blocker intolerant patients 
(Swedberg et al., 2010). 
4.2 Metabolic modulators 
Metabolic modulators target molecular metabolism within the myocardium and decrease 
consumption of FFA while increasing metabolism of glucose. Currently these drugs are 
used as antianginals as they increase energy efficiency in myocardium. Inhibitor of final 
enzyme in -oxidation of FFA trimetazidine improves myocardial energy stores by 
increasing myocardial ATP/phosphocreatine levels (Aussedat et al., 1993). Trimetazidine 
improved LVEF and NYHA class in a study in 65 heart failure patients (Fragasso et al., 
2006). Notably, benefits were more in nonischemic cardiomyopathy than the ischemic 
cardiomyopathy subgroup. Similarly perhexiline inhibit FFA metabolism and has 
demonstrated substantial improvements in LVEF, VO2max and quality of life in a clinical 
trial with 56 heart failure patients (Lee et al., 2005). However, hepatotoxicity and peripheral 
neuropathy associated with perhexiline limits its clinical utility. Ranolazine is a third 
metabolic modulator which can potentially be used in CMCM to switch from FFA to 
glucose. 
Although role of thyroid hormone therapy in treatment of heart failure is still not clear, its 
role in improvement of LV function, remodeling and microcirculation are being 
investigated. Use of l-thyroxin both in frank cases of hypothyroid and subclinical 
hypothyroid has shown reversal of structural abnormalities detected by echocardiography 
and is accompanied by clinical improvement. Gene therapies to modify thyroid hormone 
receptor or deiodinase expression and activity along with thyroid hormone replacement 
with T3 and/or T4, use of thyroid hormone analogs (e.g. diiodothyropropionic acid) will 
need further studies for proving its efficacy and safety in management of such cases  
(Gerdes & Iervasi, 2010). 
4.3 Emerging therapies 
4.3.1 AGE inhibitors and breakers 
It is well established that AGEs, a heterogeneous group of molecules formed by the non-
enzymatic reaction of reducing sugars with free amino groups of proteins, lipids and 
nucleic acids contribute significantly to diabetic complications, both macro- and micro-
vascular.  
4.3.1.1 Pharmacological intervention against AGE formation in vivo  
Classically, efforts to target AGE-related complications had been approached either with 
intentions to inhibit the ongoing process of AGE formation or to cleave already formed AGE 
protein-protein crosslinks.  
4.3.1.2 Pharmacological approach to inhibition of AGE crosslink formation 
Accumulation of substantial evidence indicating AGEs as one of the culprits for diabetic 
complications, triggered active search for intervention in the process “by pharmacological 
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approaches. Careful study of structural aspects lead researchers to target ketone group of 
the 1-amino-1-deoxyfructose residue in the amadori product, which was the key to 
subsequent AGE-forming reactions and that chemical deactivation of this ketone group 
would prevent AGE formation (Ulrich & Cerami, 2001).  
Aminoguanidine was one such compound identified having desirable features to be studied 
for its ability to inhibit AGE crosslink formation. Prior to be explored for its AGE inhibition 
capabilities, some published reports existed for its experimental use in humans for unrelated 
purposes, without significant side-effects. During subsequent years, several researchers 
demonstrated effectiveness of aminoguanidine in inhibiting AGE formation in vivo in a 
wide variety of systems and tissues. 
Usefulness of aminoguanidine has also been demonstrated in improving left ventricular 
end-diastolic (LVED) compliance in streptozotocin induced diabetic rats. Simultaneous 
administration of aminoguanidine with AGE-modified albumin prevented consequent 
glomerular hypertrophy (Bucala & Vlassara, 1995). Clinical utility with aminoguanidine was 
limited by its side effect potential, which was due to its inhibitory effect on diamine oxidase. 
This inhibition of diamineoxidase, results in an increase in histamine levels with attendant 
risk of vascular and respiratory complications. Aminoguanidine being a hydrazine 
derivative, its association with antihistone and antinuclear cytoplasmic antibody results in a 
clinical situation similar to lupus. 
Few other less talked inhibitors of AGE formation have been reported, however none of 
them have reached advanced trials in humans. Pyridoxamine, a derivative of vitamin B6 has 
been suggested to prevent the degradation of protein-amadori intermediates to protein-AGE 
products. It is shown to reduce hyperlipidemia and prevents AGE formation in rats (Wu et 
al., 2011; Degenhardt et al., 2002; Stitt et al., 2002). Some preliminary clinical trials evaluating 
effect in diabetic nephropathy with this agent have been performed (Williams et al., 2007). 
OPB-9195, a thiazolidine derivative has shown to be inhibitor of advanced glycation and to 
produce some benefits in attenuating progression of nephropathy in spontaneous diabetic 
rats (Nakamura et al., 1997). There is no current clinical experience with this compound nor 
is there any evidence for planned clinical trials.  
LR-90, yet another compound capable of inhibiting AGE formation is being studied for its 
usefulness pre-clinically. Evidence are available for evaluating this compound in diabetic 
nephropathy and retinopathy (Figarola et al., 2008; Bhatwadekar et al., 2008). The 
compound has also shown to possess some anti-inflammatory properties (Figarola et al., 
2007) with the potential for additional protective effects against diabetic vascular 
complications. However, future developmental strategy for this compound is not yet fully 
disclosed.  
4.3.1.3 Pharmacological approach to cleave preformed AGE cross-linkages 
Although attractive, approach to prevent AGE formation suffers from limitation of being 
unable to break preformed AGE crosslinkages. Thus, AGE breaker compounds are more 
desirable, as they open possibility for restoration of AGE damaged tissue to their original 
functionality, without relying on the body’s much-slower, removal and repair mechanisms. 
Two such molecules, a thiazolium compound alagebrium (ALT-711) and pyridinium 
derivative TRC4186 are being evaluated for the treatment of heart failure in patients who are 
metabolically challenged.   
Algebrium: Upon administration to various animal models of diabetes, it has resulted in an 
improvement in large-vessel elasticity, decrease in stiffness and peripheral resistance 
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(Wolffenbuttel et al., 1998; Candido et al., 2003), an attenuation in several functional and 
structural manifestations of diabetes related nephropathy (Peppa et al., 2006). Clinical 
studies with alagebrium in patients having uncontrolled systolic hypertension, of whom 
only an insignificant number were diabetic, found that the data did not indicate a treatment-
related benefit (Zieman et al., 2007). Pulse wave velocity and arterial pressures, indicators of 
conduit vessel stiffness, were unchanged; however, brachial flow mediated dilatation, an 
indicator of endothelial function, was improved. In the DIAMOND study in elderly and 
PEDESTAL in adults with diastolic heart failure, alagebrium significantly decreased left 
ventricular mass, improved left ventricular diastolic filling and improved effort tolerance 
assessed by the 6-minute walk test. However, the trials did not meet the primary endpoint 
of improvement in ejection fraction. Here again, diabetes or impaired control of glycemia 
was not a precondition for inclusion of patients. Subsequently, further development of this 
compound is terminated.  
TRC4186: TRC4186/TRC4149 is shown to act via multiple mechanisms, which include 
breaking of pre-formed AGE cross-links, reducing accumulation of carbohydrate as well as 
lipid derived AGEs and a potent free radical scavenging activity. Treatment of diabetic 
spontaneously hypertensive (SHR) rats, with TRC4149 resulted in a reduced AGE burden as 
evident by  reduced immunochemical staining for AGE and significant reduction in VCAM 
expression in aorta. Ultimately, the combined actions translate into better preservation of 
endothelial function as well as an improved cardiac function (Pathak et al., 2008). Evaluation 
of TRC4186 in a more complex animal model of metabolic syndrome, ob-ZSF1 rats, 
demonstrated its capability to attenuate overall disease progression. The compound 
successfully prevented rise in blood pressure following salt loading and preserved 
ventricular functions. Although the exact mechanism of AGE breaking is not very clear, 
reduction in AGE load and all ensuing downstream events, including attenuation of the 
associated inflammatory response, likely contributed to the improvement observed on 
treatment with TRC4186. These outcomes are substantially supported by suitable 
histopathological and immunohistochemical findings (Joshi et al., 2009).  
AGE breakers are likely to be beneficial in diabetic heart failure patients in whom there is 
usually a significant component of diastolic dysfunction and vascular unresponsiveness, 
when assessed for meaningful clinical endpoints such as physical attributes of Minnesota 
Living with Heart Failure Questionnaire and OUES, that are able to assess not only 
myocardial reserve but also vascular (nutritive perfusion) reserve. Other measures such as 
NT pro-BNP would be useful to assess diastolic dysfunction and fluid retention that could 
be exaggerated in patients with compromised renal function, a common co-morbidity in 
these patients. TRC4186, currently under investigation for use in diabetic patients has 
successfully completed phase 1 clinical trial and results of its phase 2 clinical trial 
Prospective Evaluation of AGE Breaker in Heart Failure (PEACH-F) are awaited.   
Researchers have also focus on the possibility of preventing AGE-RAGE interaction thereby 
preventing subsequent deleterious downstream events contributing to AGEs related 
pathophysiology. Conceptually this has been attained by infusing soluble RAGE (sRAGE), 
and by RAGE antibodies. Though it is clear that blocking AGE receptors using antibodies 
would prevent AGE-RAGE interaction; it remains yet to be elucidated as to whether sRAGE 
acts as an antagonist inhibiting RAGE dependent signaling pathways, or scavenge AGEs 
and AGE precursor from circulation (Zieman & Kass, 2004). There are presently no small 
molecule inhibitors of RAGE, and this approach has yet to be tested in clinical studies. 
www.intechopen.com
 The Evolving Face of Heart Failure Associated with Elevated Cardio-Metabolic Risk Factors  
 
479 
Finally, intracellular signalling pathways upregulated by AGEs can be inhibited by AGE 
signal transduction inhibitors (e.g. PK-C inhibitors incadronate disodium, cerivastatin, and 
curcumin) (Peyroux & Sternberg, 2006). 
4.3.2 Emerging therapy targeting mitochondrial energetics 
Visceral obesity and related cardiometabolic disorders are linked to defective mitochondrial 
biogenesis and oxidative metabolism with a decreased ATP production. The defective 
mitochondrial function, a common pathophysiologic feature of these cardiometabolic 
disorders is a key etiopathological factor exacerbating the CMCM. 
The effectiveness of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors 
to improve ventricular function in patients with heart failure, may be, due in part to the 
action of these agents in decreasing energy demand. Other compounds that may also have 
beneficial effects in hypertrophied hearts include vanadyl sulfate, which improves tolerance 
of ischemia by stimulating membrane glucose transport, and propionyl-L-carnitine, which 
prevents myocardial mechanical alterations associated with pressure overload. There is 
evidence that administration of propionyl-L-carnitine increases both glucose and palmitate 
oxidation in hypertrophied hearts and improves the efficiency of translating ATP 
production into cardiac work.  
On this basis, a restoration of metabolic demand by restoring mitochondrial energy 
efficiency may have potential as a new therapeutic treatment of the hypertensive heart and 
heart failure (Fujii et al., 2004). Although as yet no agent exists that promote mitochondrial 
biogenesis, PGC-1 alpha has generated interest. Sirt1 activators have also shown potential to 
increase mitochondrial biogenesis. The nitric oxide-cGMP–dependent pathway may also 
control mitochondrial biogenesis and may ameliorate energy deficiency in heart failure. 
Indeed, phosphodiesterase 5 inhibitors such as sildenafil that increase cGMP have, in 
preliminary studies, improved LV function and exercise capacity in heart failure.  
The implications for thyroid hormones on the efficiency of energy expenditure and the 
handling of ROS are important. One of the thyroid hormone analog, DIPTA has been tested 
for heart failure in early clinical trials; however agents with greater therapeutic margin are 
yet desirable. Thus, there is still much scope for research into the energetic effects of thyroid 
hormones. The preclinical evidence of TRC150094 has shown potential to improve 
mitochondrial substrate oxidation capacity and mitochondrial efficiency as well as improve 
various cardiometabolic risks with acceptable safety (Cioffi et al., 2010; Zambad et al., 2011). 
However this molecule is yet to be proven in a clinical setting. The discovery of such newer 
agents improving mitochondrial energetics will help to explore the role of these agents in 
the treatment of CMCM. It would be interesting to follow the progress of some 
investigational drugs such as TRC150094 which are in early clinical development. 
5. Conclusion and key learning 
 Diabetes, hypertension, dyslipidemia and thyroid dysfunction often occur 
concomitantly in metabolically challenged individuals who are overweight. When 
present together, their effect on myocardium as well as on the vasculature contribute 
significantly to the clinical manifestations of patients diagnosed with heart failure not 
predominantly due to epicardial Coronary Artery Disease (cardio-metabolic 
cardiomyopathy).  
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 Impairment in mitochondrial energetics resulting in inflexibility in fuel utilization has a 
significant role in development and progression of CMCM.  
 Currently recommended diagnostic methods such as Echocardiography and tissue 
Doppler imaging are carried out at rest and may result in underestimation of heart 
failure in the absence of a suitable provocative diagnostic method capable of assessing 
the ability of the heart to augment cardiac output (cardiac reserve) on exertional 
demand.  
 Dynamic assessment of cardiac response during exercise with assessment of peripheral 
flow, distribution and nutritive perfusion such as CPET may provide an objective and 
sensitive measure of cardiac and microvascular correlates of the composite with better 
correlation to clinical manifestation and possibly also help in more accurately assessing 
the onset and progress of cardiovascular malfunction.  
 Some of the newer emerging non-conventional diagnostic methods and therapies may 
offer a solution for the management of CMCM. 
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